New study aims to predict outcomes for elderly hodgkin lymphoma patients

NCT ID NCT07374068

Ongoing Knowledge-focused Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is collecting real-world medical data from 400 elderly patients (age 60 and older) with Hodgkin lymphoma in China. Researchers will use this information to create a model that can better predict how the disease will progress and help doctors make more personalized treatment decisions. The study does not test any new drug or treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could lead to a more accurate way to predict outcomes for elderly Hodgkin lymphoma patients, helping doctors choose the best treatment for each person.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly test a new therapy. The model may not work well for patients outside China or those with different health profiles.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN LYMPHOMA

Contacts and locations

Locations

Tianjin Cancer Hospital

Tianjin, Tianjin Municipality, 300060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.